2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006050437v1 17/11/3248    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jahnukainen, T. Articles by Vats, A. Search for Related Content PubMed PubMed Citation Articles by Jahnukainen, T. Articles by Vats, A.

Proteomic Analysis of Urine in Kidney Transplant Patients with BK Virus Nephropathy

Timo Jahnukainen^*, David Malehorn^,, Mai Sun^,, James Lyons-Weiler, William Bigbee^,, Gaurav Gupta^*, Ron Shapiro^||, Parmjeet Singh Randhawa^¶, Richard Pelikan^**, Milos Hauskrecht^,** and Abhay Vats^*

^* Department of Pediatrics, Children’s Hospital of Pittsburgh; Clinical Proteomics Facility; University of Pittsburgh Cancer Institute, University of Pittsburgh; ^|| Department of Surgery, University of Pittsburgh School of Medicine, ^¶ Department of Pathology, University of Pittsburgh Medical Center; ^** Department of Computer Science; and Department of Pathology, Cancer Biomarkers Laboratory, Center for Pathology Informatics, Benedum Oncology Informatics Center, University of Pittsburgh, Pittsburgh, Pennsylvania

Address correspondence to: Dr. Abhay Vats, Department of Pediatrics, Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213. Phone: 412-692-6120; Fax: 412-692-8569; abhay.vats{at}chp.edu

Received for publication May 5, 2006. Accepted for publication September 11, 2006.

The differentiation of BK virus–associated renal allograft nephropathy (BKVAN) from acute allograft rejection (AR) in renal transplant recipients is an important clinical problem because the treatment can be diametrically opposite for the two conditions. The aim of this discovery-phase biomarker development study was to examine feasibility of developing a noninvasive method to differentiate BKVAN from AR. Surface-enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry analysis was used to compare proteomic profiles of urine samples of 21 patients with BKVAN, 28 patients with AR (Banff Ia to IIb), and 29 patients with stable graft function. SELDI analysis showed proteomic profiles that were significantly different in the BKVAN group versus the AR and stable transplant groups. Peaks that corresponded to m/z values of 5.872, 11.311, 11.929, 12.727, and 13.349 kD were significantly higher in patients with BKVAN. Bioinformatics analyses allowed distinction of profiles of patients with BKVAN from patients with AR and stable patients. SELDI profiles also showed a high degree of reproducibility. Proteomic analysis of urine may offer a noninvasive way to differentiate BKVAN from AR in clinical practice. The identification of individual proteomic peaks can improve further the clinical utility of this screening method.

This article has been cited by other articles:

				D. L. Bohl and D. C. Brennan BK Virus Nephropathy and Kidney Transplantation Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(Supplement_1): S36 - S46. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673